<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00185185</url>
  </required_header>
  <id_info>
    <org_study_id>SE-866/27</org_study_id>
    <nct_id>NCT00185185</nct_id>
  </id_info>
  <brief_title>Olmesartan Medoxomil in Atherosclerosis</brief_title>
  <official_title>Multi-Centre Olmesartan Atherosclerosis Regression Evaluation (MORE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sankyo Pharma Gmbh</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <brief_summary>
    <textblock>
      This is a study in hypertensive patients with atherosclerosis and increased cardiovascular
      risk. The efficacy of olmesartan medoxomil on atherosclerosis is measured.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2001</start_date>
  <completion_date type="Actual">February 2006</completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of intima media thickness of the common carotid artery on the leading side of the neck.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>-Change in plaque volume in the common carotid artery or the carotid bulb.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Change of intima media thickness of the common carotid artery.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Changes of diastolic and systolic blood pressure.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>-Safety and tolerability</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">165</enrollment>
  <condition>Essential Hypertension</condition>
  <condition>Atherosclerotic Cardiovascular Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atenolol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atenolol</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>tablets</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>olmesartan medoxomil</intervention_name>
    <description>tablets</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>atenolol</intervention_name>
    <description>tablets</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Mean sitting sBP and dBP prior to randomization of 140-180/90-105 mmHg

          -  Increased cardiovascular risk, e.g.: a) documented or clinical signs of peripheral
             atherosclerotic disease stage IIa or lower; b) diabetes mellitus type 2; c) left
             ventricular hypertrophy on echo; d) current smoking; e) old myocardial infarction,
             stroke or TIA

          -  Intima-media thickness of the common carotid artery greater than or equal to 0.8 and
             less than or equal to 1.6 mm (measured ultrasonographically) or the plaque volume of
             the carotid bulb greater than or equal to 4 μl and less than or equal to 500 μl

        Exclusion Criteria:

          -  Body mass index &gt; 30

          -  Any type of known secondary hypertension

          -  Electrocardiographic evidence of 2nd or 3rd degree atrioventricular block, atrial
             fibrillation, cardiac arrhythmia requiring therapy or bradycardia at rest (&lt; 50/min)

          -  Obstructive pulmonary disease

          -  Claudicatio intermittens

          -  History or clinical evidence of any significant gastrointestinal, respiratory,
             hematological, metabolic, immunological or any other underlying disease which in the
             opinion of the investigator would interfere with the patient's participation in the
             trial

          -  Hypersensitivity or contraindication to ARBs, Beta-Blockers, HCTZ or any cross allergy

          -  Pre-treatment with ARBs or ACE inhibitors within 6 months prior to screening

          -  Treatment with disallowed medication

          -  Pregnant or breastfeeding females or females of childbearing potential without
             adequate contraception

          -  History of alcohol and/or drug abuse
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Prof. Klaus O Stumpe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medizinische Poliklinik der Friedrich-Wilhelms-Universitat, Bonn, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Munich</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2005</study_first_posted>
  <last_update_submitted>December 12, 2007</last_update_submitted>
  <last_update_submitted_qc>December 12, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 14, 2007</last_update_posted>
  <responsible_party>
    <name_title>Petra Laeis</name_title>
    <organization>Daichi Sankyo Europe, GmbH</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
    <mesh_term>Atenolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

